Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro

British Journal of Cancer

Volumn 73, Issue 4, 1996, Pages 525-530

  Sen, S ^a   Erba, E ^a   D'Incalci, M ^a   Bottero, F ^b   Canevari, S ^b   Tomassetti, A ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

5,10 dideazatetrahydrofolic acid; Folate binding protein; Ovarian carcinoma

Indexed keywords

COMPLEMENTARY DNA; FOLATE BINDING PROTEIN; FOLIC ACID; LOMETREXOL; PHOSPHOLIPASE C; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL STRAIN 3T3; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0030062634     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.91     Document Type: Article

References (32)

1. ALATI T, SHIH C, POHLAND RC, LANTZ RJ AND GRINDEY GB. (1992). Evaluation of the mechanism(s) of inhibition of the toxicity, but not the antitumor activity of Lometrexol (DDATHF) by folic acid (Abstract 2432). Proc. Am. Assoc. Cancer Res., 33, 407.
2. ANTONY AC. (1992). The biological chemistry of folate receptors. Blood, 79, 2807-2820.
3. BALDWIN SW, TSE A, GOSSETT LS, TAYLOR EC, ROSOWSKY A, SHIH C AND MORAN RG. (1991). Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry, 30, 1997-2006.
4. BEARDSLEY GP, MOROSON BA, TAYLOR EC AND MORAN RG. (1986). A new class of antifolates, 5,10-dideazatetrahydrofolic acid (DDATHF), an inhibitor of GAR transformylase with broad in viva activity (abstract 1027). Proc. Am. Assoc. Cancer Res., 27, 259.
5. BEARDSLEY GP, MOROSON BA, TAYLOR EC AND MORAN RG. (1989). A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J. Biol. Chem., 264, 328-333.
6. BENARD J, DA SILVA J, DE BLOIS MC, BOYER P, DUVILLARD P, CHIRIC E AND RIOU G. (1985). Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res., 45, 4970-4979.
7. BOTTERO F, TOMASSETTI A, CANEVARI S, MIOTTI S, MENARD S AND COLNAGHI MI. (1993). Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH 3T3 cells increases cell growth in vitro and in vivo. Cancer Res., 53, 5791-5796.
8. BRADFORD MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
9. ERBA E, SEN S, LORICO A AND D'INCALCI M. (1992). Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin. Eur. J. Cancer, 28, 66-71.
10. ERBA E, SEN S, SESSA C, VIKHANSKAYA FL AND D'INCALCI M. (1994). Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid. Br. J. Cancer, 69, 205-211.
11. FOGH J, WRIGHT WC AND LOVELESS JD. (1977). Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst., 58, 209-214.
12. GRINDEY GB, ALATI T, LANTZ R, POHLAND R AND SHIH C. (1992). Role of dietary folic acid in blocking the toxicity but not the antitumor activity of Lometrexol (DDATHF) (abstract 216). Ann. Oncol., 3 (suppl.), 113.
13. HAMILTON TC, YOUNG RC, McKOY WM, GROTZINGER KR, GREEN JA, CHU EW, WHANG-PENG J, ROGAN AM, GREEN WR AND OZOLS RF. (1983). Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res., 43, 5379-5389.
14. HUMPHREYS A, BAILEY N, LAOHAVINIJ S, SIMMONS D, ROBSON L AND CALVERT A. (1995). Amelioration of toxicity from Lometrexol (DDATHF) using oral folic acid A phase I study update (abstract P187). Br. J. Cancer, 71, 71.
15. JANSEN G, WESTERHOF GR, KATHMANN I, RIJKSEN G AND SCHORNAGEL JH. (1991). Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds. Cancer Chemother. Pharmacol., 28, 115-117.
16. KAMEN BA, JOHNSON CA, WANG MT AND ANDERSON RGW. (1989). Regulation of the cytoplasmic accumulation of 5-methyltetrahydrofolate in MA104 cells is independent of folate receptor regulation. J. Clin. Invest., 84, 1379-1386.
17. MIOTTI S, CANEVARI S, MENARD S, MEZZANZANICA D, PORRO G, PUPA SM, REGAZZONI M, TAGLIABUE E AND COLNAGHI MI. (1987). Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer, 39, 297-303.
18. MIOTTI S, ALBERTI S, FACHERIS P, MANTOVANI L, FORNARO M, STELLA M, MENARD S, CANEVARI S AND COLNAGHI MI. (1992). Membrane association and shedding of the GPI-anchored Ca-MOv18 antigen in human ovary carcinoma cells. Int. J. Cancer, 51, 499-505.
19. MORAN RG, TAYLOR EC AND BEARDSLEY GP. (1985). 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DATHF), a potent antifolate inhibitory to de novo purine synthesis (abstract 910). Proc. Am. Assoc. Cancer Res., 26, 231.
20. MORAN RG, BALDWIN SW, TAYLOR EC AND SHIH C. (1989). The 6S- and 6R-diastereomers of 5,10-dideaza-5,6,7,8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J. Biol. Chem., 264, 21047-21051.
21. MUGGIA F, MARTIN T, RAY M, LEICHMAN CG, GRUNBERG S, GILL I, MORAN R, DYKE R AND GRINDEY G. (1990). Phase I study of weekly 5,10-dideazatetrahydrofolate (LY 264618, DDATHF-B) (abstract 285). Proc. Soc. Clin. Oncol., 9, 74.
22. PIZZORNO G, SOKOFOSKI JA, CASHMORE AR, MOROSON BA, CROSS AD AND BEARDSLEY GP. (1991). Intracellular metabolism of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid in human leukemia cell lines. Mol. Pharmacol., 39, 85-89.
23. PIZZORNO G, CASHMORE AR, MOROSON BA, CROSS AD, SMITH AK, MARLING-CASON M, KAMEN BA AND BEARDSLEY GP. (1993). 5,10-dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. J. Biol. Chem., 268, 1017-1023.
24. PIZZORNO G, MOROSON BA, CASHMORR AR, RUSSELLO O, MAYER JR, GALIVAN J, BUNNI MA, PRIEST DG AND BEARDSLEY GP. (1995). Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res., 55, 566-573.
25. RAY MS, MUGGIA FM, LEICHMAN CG, GRUNBER SM, NELSON RL, DYKE RW AND MORAN RG. (1993). Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J. Natl Cancer Inst., 85, 1154-1159.
26. ROSS JF, CHAUDHURI PK AND RATNAM M. (1994). Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 73, 2432-2443.
27. SADASIVAN E, CEDENO MM AND ROTHENBERG SP. (1994). Characterization of the gene encoding a folate-binding protein expressed in human placenta. J. Biol. Chem., 269, 4725-4735.
28. SESSA C, GUMBRELL L, HATTY S, KERN H AND CAVALLI F. (1990). Phase I study of 5,10-dideazatetrahydrofolic acid (Ly264618; DDATHF) given daily for 3 consecutive days. Ann. Oncol., 1 (suppl.). P5:20.
29. SHIH C, GRINDEY GB, HOUGHTON PJ AND HOUGHTON JA. (1988). In vivo antitumor activity of 5,10-dideazatetrahydrofolic acid (DDATHF) and its diastereomeric isomers (abstract 1125). Proc. Am. Assoc. Cancer Res., 29, 283.
30. 10-substituted analogues. J. Med. Chem., 32, 1517-1522.
31. WESTERHOF GR, JANSEN G, VAN EMMERIK N, KATHMANN I, RIJKSEN G, JACKMAN AL AND SCHORNAGEL JH. (1991). Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated. Cancer Res., 51, 5507-5513.
32. YOUNG C, CURRIE V, BALTZER L, TROCHANOWSKI B, ETON O, DYKE R AND BOWSHER R. (1990). Phase I and clinical pharmacologic study of LY264618, 5,10-dideazatetrahydrofolate (abstract 1053). Proc. Am. Assoc. Cancer Res., 31, 177.